Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Horizon Therapeutics plc < Previous 1 2 3 4 5 6 Next > Rule 17(e) Announcement - Horizon Therapeutics plc October 06, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 17(d) Announcement – Horizon Therapeutics plc October 05, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) October 03, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) October 02, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023 October 02, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) September 29, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes September 29, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) September 27, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry September 26, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) September 25, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List September 19, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata September 13, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement September 06, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement September 05, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups August 23, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc - Rule 2.12 Announcement August 09, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results August 08, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) July 28, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients July 27, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint July 21, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023 July 17, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology July 06, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) June 30, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) June 26, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED) June 22, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration June 17, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks June 17, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement June 12, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD) June 12, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open June 06, 2023 From Horizon Therapeutics plc Via Business Wire Tickers HZNP < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.